- Home
- CRON vs ABUS Comparison
CRON vs ABUS Comparison
Compare CRON & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | ABUS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 884.7M |
| IPO Year | 2015 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CRON | ABUS |
|---|---|---|
| Price | $2.55 | $4.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 1.0M | ★ 2.2M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,587,000.00 | $6,171,000.00 |
| Revenue This Year | $32.15 | $125.30 |
| Revenue Next Year | $10.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.63 | N/A |
| 52 Week Low | $1.60 | $2.71 |
| 52 Week High | $3.43 | $5.10 |
Technical Indicators
Market Signals| Indicator | CRON | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 43.73 |
| Support Level | $2.44 | $4.23 |
| Resistance Level | $2.59 | $4.76 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 30.33 | 6.25 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.